Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 1 3

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Breast 3Genitourinary 2Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Glioblastoma 69Glioma 26Brain Neoplasms 26Gliosarcoma 23Melanoma 17Central Nervous System Neoplasms 14Astrocytoma 12Neuroblastoma 10Rhabdomyosarcoma 8Small Cell Lung Carcinoma 6Sarcoma, Ewing 6Neoplasms 6Neoplasm Metastasis 6Medulloblastoma 6Recurrence 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Oligodendroglioma 4Wilms Tumor 3Prostatic Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Ependymoma 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Rhabdoid Tumor 2Pancreatic Neoplasms 2Optic Nerve Glioma 2Lymphoma, Follicular 2Lymphoma 2

Interventions

Trastuzumab 61Paclitaxel 57Cyclophosphamide 44pembrolizumab 35Fulvestrant 34Capecitabine 29Carboplatin 27Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 14durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Temozolomide × Clear all
NCT05417594 2026-05-05

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Sapience Therapeutics

Phase 1/2 Active not recruiting
125 enrolled
BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT03190967 2023-10-11

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
12 enrolled 16 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡